Burkitt Lymphoma Clinical Trials

77 clinical trials for Burkitt Lymphoma across international registries, including 24 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma — RECRUITING · PHASE1
• AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas — RECRUITING · PHASE1
• LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies — RECRUITING · PHASE1
• Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) — RECRUITING · PHASE1
• Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene — RECRUITING · PHASE1
• Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) — RECRUITING · PHASE1
• CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT — RECRUITING · NA
• Allo HSCT Using RIC and PTCy for Hematological Diseases — RECRUITING · PHASE2
• Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas — RECRUITING · PHASE1
• Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders — RECRUITING · PHASE2
• Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma — RECRUITING · PHASE1
• Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution — RECRUITING
• Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies — RECRUITING · PHASE2
• MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing — RECRUITING · NA
• Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma — RECRUITING · PHASE2
• Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma — RECRUITING · PHASE1
• Recommendations for the Treatment of Children With Burkitt's Lymphoma — RECRUITING
• Study of SGR-1505 in Mature B-Cell Neoplasms — RECRUITING · PHASE1
• Long-term Follow-up Study of Patients Receiving CAR-T Cells — RECRUITING
• Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL — RECRUITING · PHASE2
• Thiotepa, Cyclophosphamide, Clarithromycin and Cytarabine — RECRUITING · PHASE1
• Immunotherapy in Lymphoma — RECRUITING
• B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021 — RECRUITING · PHASE4
• Effects of endurance exercise on incidence and severity of cognitive impairments and other therapy-related side effects in leukemia and lymphoma patients undergoing high-dose chemotherapy. A randomized controlled trial. — RECRUITING
• ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies — COMPLETED · PHASE1
• Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma — ACTIVE_NOT_RECRUITING · PHASE1
• ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies — COMPLETED · PHASE1
• Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T — COMPLETED · PHASE1
• Secondary Immunodeficiencies and Infections in patients with hematologic malignancies treated with anti-CD20-antibodies — OTHER
• Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy — ACTIVE_NOT_RECRUITING · PHASE2
• Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies — COMPLETED · PHASE2
• Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine — COMPLETED · PHASE1
• Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas — ACTIVE_NOT_RECRUITING · PHASE1
• Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies — ACTIVE_NOT_RECRUITING · PHASE1
• Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma — NOT_YET_RECRUITING · PHASE1
• Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma — COMPLETED · PHASE2
• A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy — COMPLETED · PHASE1
• Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease — COMPLETED · PHASE2
• Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma — ACTIVE_NOT_RECRUITING · PHASE2
• HOVON 127 BL / SAKK 37/16: Phase III study comparing R-CODOX-M/R-IVAC versus dose-adjusted EPOCH-R (DA-EPOCH-R) for patients with newly diagnosed high risk Burkitt lymphoma — TERMINATED · PHASE3
• Blood Sample Markers of Reproductive Hormones in Assessing Ovarian Reserve in Younger Patients With Newly Diagnosed Lymphomas — COMPLETED
• CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies — COMPLETED · PHASE1
• Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas — TERMINATED · PHASE1
• Immune Responses to COVID-19 Vaccination in Lymphoma Patients — COMPLETED
• A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001) — COMPLETED · PHASE1
• Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda — TERMINATED · PHASE1
• Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma — OTHER · PHASE3
• Mobile Health Case Management System for Reducing Pediatric Treatment Abandonment — COMPLETED · NA
• Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma — COMPLETED · PHASE2
• GastroIntestinal Cancer in Children and Adolescents — OTHER

Refine this search